1. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
- Author
-
Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, and Farag SS
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Arsenic Trioxide, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Drug Evaluation, Humans, Middle Aged, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Arsenicals administration & dosage, Multiple Myeloma drug therapy, Oxides administration & dosage
- Abstract
In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As(2)O(3)) with DVd (Doxiltrade mark, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd. more...
- Published
- 2008
- Full Text
- View/download PDF